Assessing eligibility for treatment in acute myeloid leukemia in 2023-Reference-Cited by-同舟云学术

Assessing eligibility for treatment in acute myeloid leukemia in 2023

Published:2023-03-04 Issue:3 Volume:16 Page:181-190
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Venditti Adriano¹^ORCID,Cairoli Roberto²,Caira Morena³,Finsinger Paola³,Finocchiaro Fabio³,Neri Benedetta³,De Benedittis Daniela³,Rossi Giuseppe⁴,Ferrara Felicetto⁵

Affiliation:

1. Ematologia, Dipartimento di Biomedicina e Prevenzione, Università di Roma “Tor Vergata”, Rome, Italy

2. Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Grande Ospedale Metropolitano Niguarda-Milano, Milan, Italy

3. Medical Department, AbbVie srl, Campoverde di Aprilia, Latina, Italy

4. Ematologia, ASST degli Spedali Civili, Brescia, Italy

5. Divisione di Ematologia, Ospedale Antonio Cardarelli, Naples, Italy

Funder

bbVie sponsored this review and participated in the design

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2023.2185603

Reference77 articles.

1. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

2. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017

3. Acute myeloid leukemia in the elderly: therapeutic options and choice

4. SEER cancer stat facts: acute myeloid leukemia [Internet]. Bethesda (MD): National Cancer Institute; 2017. [cited 2022 Nov 29]. Available from: http://seer.cancer.gov/statfacts/html/amyl.html.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flow cytometry in acute myeloid leukemia and detection of minimal residual disease;Clinica Chimica Acta;2025-01

2. Treatment of Acute Myeloid Leukemia in the Community Setting;The Oncologist;2024-08-19

3. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda;Cancers;2024-01-16